Search
for
Sort by
Research 61–90 of 1000+
- Pharmacokinetics of a new testosterone transdermal delivery system, TDS<sup>®</sup>‐testosterone in healthy males
- Pharmacokinetics of 2 Novel Formulations of Modified-Release Oral Testosterone Alone and With Finasteride in Normal Men With Experimental Hypogonadism
- Pharmacokinetics of Finasteride in the Elderly Volunteers.
- Pharmacokinetics of Modified Slow-Release Oral Testosterone over 10 Days in Normal Men with Experimental Hypogonadism
- Pharmacokinetics and Bioconversion of Dehydroepiandrosterone after Application of Dexamethasone in Women with Polycystic Ovary Syndrome
- Pharmakokinetik und Biokonversion von Dehydroepiandrosteron nach Dexamethason-Vorbehandlung bei Frauen mit dem Syndrom der polyzystischen Ovarien
- Pharmacogenetic analysis of human steroid 5α reductase type II: comparison of finasteride and dutasteride
- Pharmacogenetic Determinants of Valproic Acid Efficacy, Toxicity, and Serum Levels in Genetic Generalized Epilepsy
- Local Pharmacokinetics and Tolerability of Topically‐Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia
- The Pharmacokinetics of 2.5- to 10-mg Oral Doses of Minoxidil in Healthy Volunteers
- Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry
- Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches
- In vivo Pharmacokinetic Interactions of Finasteride and Identification of Novel Metabolites
- A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation
- Dihydroartemisinin loaded nanostructured lipid carriers (DHA-NLC): evaluation of pharmacokinetics and tissue distribution after intravenous administration to rats.
- A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function
- Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
- Oral Testosterone in Oil: Pharmacokinetic Effects of 5 Reduction by Finasteride or Dutasteride and Food Intake in Men
- Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
- Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.
- Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride
- Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation.
- A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers
- Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation
- Rp-HPLC Determination of Quercetin in a Novel D-α-Tocopherol Polyethylene Glycol 1000 Succinate Based SNEDDS Formulation: Pharmacokinetics in Rat Plasma
- Spanlastic Nano-Vesicles: A Novel Approach to Improve the Dissolution, Bioavailability, and Pharmacokinetic Behavior of Famotidine
- Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
- Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators